Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
58.46 USD | -5.86% | -9.52% | -29.50% |
May. 09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.50% | 6.51B | |
+5.38% | 109B | |
+11.37% | 105B | |
-0.38% | 22.25B | |
-12.05% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.41% | 16.85B | |
+2.95% | 13.76B | |
+35.83% | 12.46B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market